Remimazolam

Generic Name: Remimazolam

Brand Names: Byfavo

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₁₉BrN_₄O_₂

CAS Number: 308242-62-8

Unique Ingredient Identifier: 7V4A8U16MB

Background: Remimazolam is an ultra short-acting benzodiazepine used in the induction and maintenance of sedation during short (<30 minute) procedures. Recent trends in anesthesia-related drug development have touted the benefits of so-called "soft drugs" - these agents, such as remifentanil, are designed to be metabolically fragile and thus susceptible to rapid biotransformation and elimination as inactive metabolites. These "soft drugs" are useful in the context of surgical procedures, wherein a rapid onset/offset is desirable, enabling anesthesiologists to manipulate drug concentrations as needed. Remimazolam was the first "soft" benzodiazepine analog to be developed and was approved for use by the FDA in July 2020 under the brand name Byfavo.

Indication: Remimazolam is indicated for the induction and maintenance of procedural sedation in adults undergoing procedures lasting 30 minutes or less.

Associated Conditions: Procedural Sedation

Clinical Trials

The Effect of Wavelet Index in Monitoring the Sedation Depth of Remimazolam Besylate

Not yet recruiting

Conditions: Sedative, Hypnotic, or Anxiolytic Withdrawal
Remimazolam
Anesthesia Awareness

Interventions: Drug: Remimazolam besylate

First Posted Date: 2024-05-24

Last Posted Date: 2024-06-25

Lead Sponsor: Beijing Chao Yang Hospital

Target Recruit Count: 30

Registration Number: NCT06427785

Paradoxical Reactions of Remimazolam in Pediatric Painless Gastrointestinal Endoscopy

Not Applicable

Completed

Conditions: Endoscopy, Gastrointestinal

Interventions: Drug: Remimazolam

First Posted Date: 2024-05-17

Last Posted Date: 2024-10-30

Lead Sponsor: Tongji Hospital

Target Recruit Count: 333

Registration Number: NCT06419543

Locations: 🇨🇳
Tongji hospital, Wuhan, Hubei, China

Remimazolam for Emergence Delirium Prevention in Patients Undergoing Rhinoseptoplasty, FESS or Septoplasty

Phase 2

Recruiting

Conditions: Remimazolam
Emergence Delirium
Rhinoplasty

Interventions: Drug: Remimazolam 20 MG Injection [Byfavo]
Drug: NaCl 0.9%

First Posted Date: 2024-05-03

Last Posted Date: 2024-05-03

Lead Sponsor: University Hospital of Split

Target Recruit Count: 80

Registration Number: NCT06398275

Locations: 🇭🇷
UH Split, Split, Croatia

Effect of Combined Administration of Sevoflurane and Remimazolam on Emergence

Not Applicable

Recruiting

Conditions: Gynecological Surgery

Interventions: Drug: Remimazolam

First Posted Date: 2024-04-25

Last Posted Date: 2024-06-07

Lead Sponsor: Pusan National University Yangsan Hospital

Target Recruit Count: 24

Registration Number: NCT06385002

Locations: 🇰🇷
Pusan National University Yangsan Hospital, Yangsan, Korea, Republic of

Comparison of Remimazolam and Propofol Combination vs. Propofol in IOM

Phase 4

Not yet recruiting

Conditions: Neurologic Disorder

Interventions: Drug: Remimazolam besylate + propofol MCT
Drug: Propofol MCT

First Posted Date: 2024-04-24

Last Posted Date: 2024-04-24

Lead Sponsor: Chung-Ang University Gwangmyeong Hospital

Target Recruit Count: 56

Registration Number: NCT06382467

Comparison of Remimazolam and Propofol Effect on Oxygen Reserve During Endoscopic Retrograde Cholangiopancreatography

Not Applicable

Recruiting

Conditions: Hepatobiiliary Diseases Requiring Endoscopic Retrograde Cholangiopancreatography

Interventions: Drug: Remimazolam besylate
Drug: Propofol

First Posted Date: 2024-04-11

Last Posted Date: 2024-04-11

Lead Sponsor: Yonsei University

Target Recruit Count: 112

Registration Number: NCT06359834

Locations: 🇰🇷
Division of Gastroenterology, Department of Internal Medicine, Yonsei Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Korea, Republic of